Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Net: 2021-2025

Historic Receivables - Net for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Sep 2025 value amounting to $72.6 million.

  • Tarsus Pharmaceuticals' Receivables - Net rose 149.05% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 149.05%. This contributed to the annual value of $46.8 million for FY2024, which is 181.33% up from last year.
  • Tarsus Pharmaceuticals' Receivables - Net amounted to $72.6 million in Q3 2025, which was up 24.49% from $58.3 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Receivables - Net high stood at $72.6 million for Q3 2025, and its period low was $17,000 during Q1 2022.
  • Moreover, its 3-year median value for Receivables - Net was $29.7 million (2024), whereas its average is $35.3 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Receivables - Net crashed by 99.93% in 2022 and then surged by 31,441.18% in 2023.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Receivables - Net stood at $20.0 million in 2021, then tumbled by 99.91% to $17,000 in 2022, then skyrocketed by 31,441.18% to $16.6 million in 2023, then soared by 181.33% to $46.8 million in 2024, then surged by 149.05% to $72.6 million in 2025.
  • Its last three reported values are $72.6 million in Q3 2025, $58.3 million for Q2 2025, and $62.4 million during Q1 2025.